Joint Programming Initiative on Antimicrobial Resistance

AMR Research Funding Mapping (2015): A mapping exercise on scientific research in the area of antimicrobial resistance was previously conducted for the period of 2007-2013. This helped to obtain an overview of the scale of funding, research capacity and scope among JPIAMR member countries for AMR research. The study, which was the first of its kind, highlighted the need for increased and new investment across all Member States. The work was led by the UK‘s Medical Research Council (MRC) along with JPIAMR and resulted in a publication in the journal ‘THE LANCET Infectious Diseases’. The article and the report are available here.

Update of AMR Research Funding Mapping (2018): JPIAMR presently is undertaking an extensive mapping exercise on different aspects of AMR. This work is an extension and/or update of the mapping exercise performed in 2015. Each JPIAMR member country will provide data and information relevant for the following sections as listed below: 

Mapping of AMR research funding: Data on project funding will be collected from JPIAMR joint calls, national funding agencies and international foundations to monitor investments in projects ranging from basic, applied and clinical research, including trials, epidemiological, public health, veterinary and environmental research related to AMR issues. It will be built on data collected by JPIAMR in the first mapping exercise that provided an objective insight into the scale and scope of publicly funded AMR research and associated investment in participating countries. 

Mapping of AMR research projects: This will involve mapping of antimicrobial resistance research undertaken in the 26 member countries. Project data relevant to antimicrobial resistance, within the broad remit of the six priority topics identified in the JPIAMR Strategic Research Agenda will be also included in the mapping exercise. It will help to identify gaps and prioritization of specific research areas identified in the SRA. This exercise will form the baseline for AMR research and associated investment, which will help to evaluate the performance of JPIAMR over time.

Mapping of AMR research centres/units: AMR research is also carried out at specific research centres/units where (not all) funding is through competitive project grants. This mapping is focusing then in institutional funding. We would collect data about such research centres that has significant contributions to AMR research. A dynamic network of such AMR research units will provide a close contact between the JPIAMR and the scientific community and would help to build research capacity in the area of AMR. It will aim to contribute to the establishment of a Virtual Research Institute.

Mapping of AMR Research infrastructures: Limited sharing and linkage of samples, strains and data is a key barrier for AMR research. Financial and scientific investments have been committed in several member states and thousands of citizens have voluntarily contributed data and bio-specimens to biobanks and databases. Mapping of the existing AMR research infrastructure within the member states will better coordinate the databases and biobanks and would ensure effective interchange of valid information and samples. Research infrastructure mapping under the JPIAMR banner aims to harmonize resources and enhance coordination of research efforts that could be used for translational research, clinical care, personalised medicine and maximize public health benefits.

Mapping of AMR Industry alliances: The mapping exercise will be extended to an industry-focused dataset. Mapping of industries working in the AMR field and their specific needs will be conducted to improve data sharing and communication between academia and industry.

The recent WHO review shows that the current clinical pipeline is still insufficient to mitigate the threat of antimicrobial resistance. JPIAMR has contributed to the WHO antibiotic development pipeline analyses through reviewing pipeline data and advising on the method for analyses. JPIAMR is continuing its efforts to find solutions to the challenges presented by WHO by processing current and future calls that funds research on the very challenges highlighted in the report. The full report is available here.

JPIAMR also has a specific industrial focus. It aims to address the need of developing new antibiotics by supporting small and medium-sized enterprises (SMEs). This will be realized by establishing collaboration with BEAM (Biotech companies in Europe combating AntiMicrobial Resistance) Alliance who are committed to engage European small and medium biopharmaceutical companies involved in developing innovative products to tackle antimicrobial resistance.






Share this page
Tweet about this on Twitter
Share on Facebook
Share on Google+